key: cord-0737083-1qd2fbko
authors: Davis, Cristina E.; Schivo, Michael; Kenyon, Nicholas J.
title: A breath of fresh air – the potential for COVID-19 breath diagnostics
date: 2021-01-06
journal: EBioMedicine
DOI: 10.1016/j.ebiom.2020.103183
sha: 766ffbe03e582e26364bedaac4ff6a3d0b0c71b1
doc_id: 737083
cord_uid: 1qd2fbko

nan

As the world continues to grapple with the ongoing SARS-CoV-2 pandemic, it remains clear that frequent and widespread virus testing is a valuable tool to understand disease spread and to guide public health actions by communities and governments. To date, most traditional diagnostic tests continue to rely on established polymerase chain reaction (PCR) technologies, which have proven to be quite robust as a tool for mass screening and remain the gold standard within modern medicine. When employed using standardized protocols, PCR typically has a high accuracy and high specificity (eg, low false positives and low false negatives). Early in the pandemic, there were challenges to quickly establish and distribute the best testing methods. Once resolved, the test was widely and successfully rolled out in protocols across the world. However, other challenges have emerged when using this as a tool to combat COVID-19 spread.

For one, there are known sampling issues with nasopharyngeal PCR tests. While PCR itself is incredibly robust, it relies on collecting samples of actively amplifying viral genetic material. Though uncommon, it is possible to "miss" swabbing an area with active viral loads, which leads to a false-negative test result. There have been many more issues with the operational logistics and product supply chains that have strained testing systems during this public health crisis. The liquid reagents needed for the PCR test and the nasal swabs are in high demand, thus limiting availability in some locations causing alterations to planned testing protocols. Finally, although PCR is very reliable, there can be a significant time delay between sampling and when the results are available À hours-to-days, depending on processing capabilities of the test site.

Recently, a new approach to viral diagnostics has been considered by examining exhaled breath for signatures of the host-response to infection [1] . For several decades, it has been known that endogenously produced volatile organic compounds (VOCs) are present in exhaled breath, and these are frequent targets of breath diagnostics research and represent metabolic endpoints that can be quickly assessed for health information [2] . There are also reports of scent dogs being trained to detect human diseases, and observations of this phenomenon have also been recently expanded to include COVID-19 diagnosis [3, 4] . While the cellular and molecular mechanisms and fundamental understandings of breath signature VOC generation are still being developed, some prior work in cell culture models pointed to viral-associated breath VOCs for both rhinovirus [5] and seasonal influenza respiratory tract infections [6] . Specific oxidative stress VOCs were also observed post-vaccination in another previous study [7] , when a nasally-delivered attenuated live virus vaccine was used. This was also followed by at least one porcine animal study that looked at breath VOC signatures in influenza infected animals [8] .

Earlier this year, two other reports have also tentatively linked specific breath VOCs with SARS-CoV-2 infections [9, 10] , and clearly this emerging area is likely to continue to yield interesting results.

A study recently published in EBioMedicine by Grassin-Delyle et al. [1] measured very specific VOCs in exhaled breath from mechanically ventilated adults with COVID-19 and compared that signature to control ventilated patients with non-COVID acute respiratory distress syndrome. As in the studies published by Ruszkiewicz et al. and Shan et al., this third group has also shown that COVID-19 associated breath signatures can specifically distinguish infection À in this case with 93% accuracy. While ongoing work is still needed to confirm these results in larger cohorts, it represents a potential rapid nearreal-time test that could be deployed to augment PCR testing strategies. Even if not used as a final confirmatory measure, the rapid nature of this reagent-free, logistically simple test may be useful for high throughput screening of asymptomatic cases in large or unique populations (eg, prior to boarding an airplane, or entering a sports stadium).

While still a very new approach, there are benefits to considering breath testing for SARS-CoV-2 infections. When coupled with several of the near-real-time VOC detectors that are under development or recently available, it may provide a quick test À potentially yielding results in minutes, before a subject has left the testing area. This could lead to higher quarantine compliance and limit community spread, as there is no latency lag-time for asymptomatic or pre-symptomatic individuals. While the promise of vaccine deployment is tantalizingly close, it is clear that society will need to continue to test for SARS-CoV-2 infections for some time. These rapid breath-based tests could be a

Metabolomics of exhaled breath in critically ill COVID-19 patients: a pilot study

Breathborne biomarkers and the human volatilome

Scent dog identification of samples from COVID-19 patients À a pilot study

Detection dogs as a help in the detection of COVID-19 Can the dog alert on COVID-19 positive persons by sniffing axillary sweat samples? Proofof-concept study

Volatile emanations from in vitro airway cells infected with human rhinovirus

Cellular Scent of Influenza Virus Infection

Effect of influenza vaccination on oxidative stress products in breath

VOC breath profile in spontaneously breathing awake swine during Influenza A infection

Diagnosis of COVID-19 by analysis of breath with gas chromatography-ion mobility spectrometry -a feasibility study

Multiplexed nanomaterial-based sensor array for detection of COVID-19 in exhaled breath

The authors are supported by NIH National centre for Advancing Translational Sciences (NCATS) through award UL1 TR001860 (CED, NJK); NIH award UG3-OD023365 (CED, NJK); NIH award 1P30ES023513-01A1 (CED, NJK), the Veteran's Administration (CED, MS, NJK), the University of California Tobacco-Related Disease Research Program award T31IR1614 (CED, NJK), and a University of California CITRIS award 19-0092 (CED, MS, NK). The contents of this commentary are solely the responsibility of the authors and do not necessarily represent the official views of the funding agencies.